Astrazeneca (AZN) Accounts Payables (2016 - 2026)

Astrazeneca has reported Accounts Payables over the past 18 years, most recently at -$22.5 billion for Q1 2026.

For Q1 2026, Accounts Payables changed 0.17% year-over-year to -$22.5 billion; the TTM value through Mar 2026 reached -$22.5 billion, changed 0.17%, while the annual FY2025 figure was -$25.3 billion, 212.53% down from the prior year.
Accounts Payables for Q1 2026 was -$22.5 billion at Astrazeneca, up from -$25.3 billion in the prior quarter.
Over five years, Accounts Payables peaked at $22.5 billion in Q4 2024 and troughed at -$25.3 billion in Q4 2025.
A 5-year average of -$14.5 billion and a median of -$19.7 billion in 2023 define the central range for Accounts Payables.
Biggest five-year swings in Accounts Payables: skyrocketed 777.41% in 2023 and later tumbled 212.53% in 2025.
Year by year, Accounts Payables stood at $2.6 billion in 2022, then skyrocketed by 777.41% to $22.4 billion in 2023, then rose by 0.41% to $22.5 billion in 2024, then tumbled by 212.53% to -$25.3 billion in 2025, then rose by 10.98% to -$22.5 billion in 2026.
Business Quant data shows Accounts Payables for AZN at -$22.5 billion in Q1 2026, -$25.3 billion in Q4 2025, and -$25.0 billion in Q3 2025.

Peer Comparison